FULC Latest Headlines

Truist Financial Sticks to Their Buy Rating for Fulcrum Therapeutics (FULC)

at www.tipranks.com (Mon, 2-Feb 7:58 AM)

FULC’s $150 Million Public Offering Targets R&D and Growth—Will Expanded Funding Accelerate Innovation?

Market Chameleon (Tue, 9-Dec 8:39 AM)

Inducement Stock Options Grant Highlights Fulcrum Therapeutics’ Talent Strategy as Shares Surge

Market Chameleon (Mon, 8-Dec 9:54 AM)